Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.70 |
| ▸ | FAAH | O00519 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CES2 | O00748 | 3/20 | 0.59 |
| ▸ | CES1 | P23141 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.56 |
| ▸ | PPARG | P37231 | 6/20 | 0.56 |
| ▸ | PPARD | Q03181 | 6/20 | 0.56 |
| ▸ | PPARA | Q07869 | 6/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | FABP4 | P15090 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31607656 | 1.00 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL28937158 | 1.00 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL1803511 | 1.00 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL6684216 | 1.00 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL31520297 | 1.00 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL31168145 | 1.00 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL7769117 | 1.00 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL5932679 | 1.00 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL19359738 | 1.00 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL10481745 | 1.00 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658663-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250034081-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2025-01-30 | — | — | US | disclosed |
| WO-2024163262-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| CN-116348084-A | Cosmetic compositions, kits, and methods of making and using the same | 莱雅公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116018127-A | Cosmetic compositions, kits, and methods of making and using the same | 莱雅公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11634379-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2023-04-25 | — | — | US | disclosed |
| EP-4148083-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | disclosed |
| EP-3766916-B1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2022-09-28 | — | — | EP | disclosed |
| US-20210107861-A1 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2021-04-15 | — | — | US | disclosed |
| EP-3766916-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics Inc. (CA) | 2021-01-20 | — | — | EP | disclosed |
| US-20140212654-A1 | PRESSURE SENSITIVE COATING FOR IMAGE FORMING | CHROMATIC TECHNOLOGIES, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2013115800-A1 | THERMOCHROMIC SYSTEMS WITH CONTROLLED HYSTERESIS | CHROMATIC TECHNOLOGIES, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20130193386-A1 | THERMOCHROMIC SYSTEMS WITH CONTROLLED HYSTERESIS | CHROMATIC TECHNOLOGIES, INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2013106420-A1 | REVERSIBLE THERMOCHROMIC AND PHOTOCHROMIC INK PENS AND MARKERS | CHROMATIC TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130177703-A1 | REVERSIBLE THERMOCHROMIC AND PHOTOCHROMIC INK PENS AND MARKERS | CHROMATIC TECHNOLOGIES INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2006012640-A2 | METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS | DARPHARMA, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1084860-B1 | Thermochromic microencapsulated pigments | PILOT INK CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6494950-B1 | FOUR ESSENTIAL COMPONENTS (A) AN ELECTRON-DONATING CHROMATIC ORGANIC COMPOUND, (B) AN ELECTRON-ACCEPTING COMPOUND, (C) A REACTION MEDIUM DETERMINING THE TEMPERATURES AT WHICH THE COLOR REACTIONS OF COMPONENT (A) WITH COMPONENT (B) TAKE | THE PILOT INK CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-1084860-A2 | Thermochromic microencapsulated pigments | THE PILOT INK CO., LTD. (JP) | 2001-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634379-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | APOB, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HSP90AA1 4009/4885FAAH 2300/4885MEN1 2166/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | HSP90AA1 3653/4885FAAH 481/4885MEN1 4494/4885 |
| US-20250034081-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | HNRNPA2B1, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HSP90AA1 4170/4885FAAH 2397/4885MEN1 2311/4885 |
| US-20210107861-A1 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | APOB, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HSP90AA1 4009/4885FAAH 2300/4885MEN1 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.